ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Allostatic Load, Multimorbidity, and Overall and Cancer-Specific Survival among Older Adults in the United States.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBoth allostatic load (AL), a measure of cumulative physiologic stress, and multimorbidity, the presence of multiple chronic conditions, have been linked to poorer survival in older adults. However, associations remain understudied.
methodsUsing the nationally representative National Health and Nutrition Examination Survey data from 1999 to 2018 with the 2019 Linked Mortality File, weighted Cox regression models estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) for the associations of AL and multimorbidity with overall survival (OS) and cancer-specific survival. AL consisted of nine biomarkers, assigning one point for each exceeding predefined clinically relevant cutoffs, for a total AL score (range: 0-9; high AL ≥3). Multimorbidity was defined as having ≥2 of 11 chronic conditions.
resultsParticipants (N = 3,484 adults ≥60 years with self-reported cancer) were on average 73 years of age, 46% female, 71% non-Hispanic White, 59% had high AL, and 64% had multimorbidity. Overall, 46% of participants died of any cause, including 484 cancer-specific deaths. High AL and multimorbidity were both associated with poorer OS [HR (95% CI) = 1.33 (1.15-1.54) and 1.40 (1.21-1.62), respectively] and moderately for cancer-specific survival. Results were similar for sex-specific AL cutoffs, incorporating medication use, excluding individuals <65 years, and mutually adjusting for AL and multimorbidity.
conclusionsAmong older adults with cancer, high AL and multimorbidity are associated with poorer OS. Interventions that improve chronic condition management may reduce AL and multimorbidity and improve survival for older cancer survivors. IMPACT: Assessing AL and multimorbidity could help identify high-risk older cancer survivors and inform survivorship care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.